FTO and metabolic dysfunction-associated steatotic liver disease: Analogously, in vitro and vivo research of glucocorticoid‐induced NAFLD demonstrate that glucocorticoid receptor‐dependent FTO transactivation and m6A demethylation on the mRNA of lipogenic genes, such as SREBF1 and SCD, activation of these lipogenic genes and lipid accumulation in the liver.52